

ASX Market Announcement



Non-renounceable Entitlement Offer: extension of Closing Date

Melbourne Australia, August 28, 2024: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, "Company", "GTG"), a global leader in genomics-based tests in health, wellness and serious disease and the parent company of geneType™, is pleased to announce that, including the Directors' underwriting, it has received interest of just under \$1 million for its Non-renounceable Entitlement Offer.

The Company has resolved to extend the Closing Date for its Non-renounceable Entitlement Offer by one (1) week to **5pm (AEST) Monday, 9 September 2024**. The decision to extend the Closing Date is to allow Eligible Shareholders additional time to evaluate the Entitlement Offer. The Company has sought interest from licensed brokers in respect of any shortfall under the Entitlement Offer. No allotments will be made under the Entitlement Offer unless the minimum subscription of \$2 million (including Directors' underwriting) is achieved. Therefore, if Eligible Shareholders wish to take up more than their entitlement under the Entitlement Offer they should also apply under the "To-Up Offer". See the Entitlement Offer prospectus for further information.

On 26 July, 2024 the Company announced that Eligible Shareholders holding Shares may subscribe under the Entitlement Offer for 2 New Shares for every 3 Shares held as at the Record Date of 7.00 pm on 7 August 2024, which Entitlement Offer includes the issue to the subscribers of 1 New Option for every New Share issued under the Entitlement Offer (including 1 New Option for every New Share issued under any Shortfall) (**Entitlement Offer**). The issue price for New Shares is \$0.04 (4 cents) per New Share to raise a minimum of \$2 million and up to a maximum of \$3.88 million, before costs (upon placement of entitlements to any shortfall).

The Entitlement Offer is available to Eligible Shareholders with a registered address in Australia and New Zealand as at the Record Date, and therefore excludes USA residents where the majority of shares are held.

As referred to above, the Closing Date for the Entitlement Offer has now been extended by one (1) week to 5pm (AEST) Monday, 9 September 2024.

The revised indicative time table for the Entitlement Offer is set out below:

Event	Date
Capital Raising announcement	25 July 2024
Lodgement of Prospectus with ASIC and ASX	2 August 2024
Record Date	7 August 2024
Dispatch of letter advising of access to Prospectus, prospectus available online and Entitlement Offer opens	12 August 2024
Entitlement Offer closes	9 September 2024
Allotment and issue of New Shares under Entitlement Offer (before noon)	17 September 2024

The above dates / times are indicative and subject to change. All times / dates are in reference to Melbourne Time

- END -

Authorised for release by the Board of Directors.

For inquiries, contact:

Peter Rubinstein

E: investors@genetype.com

About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType™ and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit www.genetype.com

About EasyDNA

EasyDNA is an online provider of genetic testing services established in 2007 and developed into an online network of over 70 websites in over 42 countries. EasyDNA's network of online retail sales platforms offers fast and affordable home DNA testing that is reliable and confidential. They also offer a number of lifestyle and health and wellbeing tests, and animal testing relating to allergies and tolerances. EasyDNA is a pioneering provider of genetic testing services, dedicated to delivering accurate and confidential results to individuals and organizations worldwide.

Forward Looking Statements

This announcement may contain forward-looking statements about the Company's expectations, beliefs or intentions regarding, among other things, statements regarding the expected use of proceeds. In addition, from time to time, the Company or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by the Company with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of the Company's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. As forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause the Company's actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause the Company's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements as detailed in the Company's filings with the Securities and Exchange Commission and in its periodic filings with the ASX in Australia and the risks and risk factors included therein. In addition, the Company operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. The Company does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.